ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42649986

Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.

Kos M and 7 others. Cancers (Basel), 2026. Cited by 0 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers. Papers, record 42649986. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42649986

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-29
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kos MMarek
2Bojarski KKrzysztof
3Czosnek MMilena
4Śnieżyński JJanhttps://orcid.org/0000-0003-4979-2726
5Wilczyński BBartosz
6Mertowska PPaulinahttps://orcid.org/0000-0001-9530-6659
7Grywalska EEwelina
8Mertowski SSebastianhttps://orcid.org/0000-0002-7121-1396

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
DS640Medical University of LublinPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References209

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140,860,556Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer.Front Public Health2025https://conductscience.org/library/papers/40860556PubMed
240,454,643Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.N Engl J Med2025https://conductscience.org/library/papers/40454643PubMed
342,042,562Antibody-Drug Conjugates in Gastrointestinal Oncology: Clinical Efficacy and Inpatient Toxicity Management.J Pers Med2026https://conductscience.org/library/papers/42042562PubMed
440,700,298Immunotherapy in GI Cancers: Lessons from Key Trials and Future Clinical Applications.Antibodies (Basel)2025https://conductscience.org/library/papers/40700298PubMed
537,005,190The Role of Immunotherapy in Esophageal and Gastric Cancer.Clin Colorectal Cancer2023https://conductscience.org/library/papers/37005190PubMed
619,789,532Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.Br J Cancer2009https://conductscience.org/library/papers/19789532PubMed
740,205,008FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies: A Systematic Review.J Gastrointest Cancer2025https://conductscience.org/library/papers/40205008PubMed
828,476,144Multi-omics approaches to disease.Genome Biol2017https://conductscience.org/library/papers/28476144PubMed
932,416,072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
1028,736,636Biological agents in gastrointestinal cancers: adverse effects and their management.J Gastrointest Oncol2017https://conductscience.org/library/papers/28736636PubMed

1 to 10 of 209

See all 209 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

None in this release.

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene
PDCD15,133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42649986

GET https://conductscience.org/api/papers/v1/42649986/references?page=2

API referenceFor AI assistants